Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TNGX with free AI briefings, catalyst countdowns, and dilution alerts.

TNGX · Tango Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$977.5M Cash on Hand
77.2mo Cash Runway
Follow TNGX by email Get an email when TNGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TNGX, unsubscribe in one click. Privacy

📣 What TNGX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Pan-RAS Molecular Glue ERAS-0015 PDAC Phase 1/2 · NCT07897734 Not yet recruiting
Nab-paclitaxel PDAC Phase 1/2 · NCT06922591 Recruiting
mFOLFIRINOX PDAC Phase 1/2 · NCT06922591 Recruiting
Daraxonrasib (RMC-6236) PDAC Phase 1/2 · NCT06922591 Recruiting
Zoldonrasib (RMC-9805) PDAC Phase 1/2 · NCT06922591 Recruiting
MAT2A Inhibitor S-095035 MTAP-deleted Solid Tumors Phase 1/2 · NCT06188702 Active not recruiting
CoREST Inhibitor TNG260 Non Small Cell Lung Cancer Phase 1/2 · NCT05887492 Active not recruiting
USP1 Inhibitor TNG348 Breast Cancer Phase 1/2 · NCT06065059 Terminated
PRMT5 Inhibitor TNG456 Non Small Cell Lung Cancer Phase 1/2 · NCT06810544 Recruiting
Vopimetostat (TNG462) Locally Advanced Solid Tumor Phase 1/2 · NCT05732831 Recruiting
Ralometostat (TNG908) Locally Advanced Solid Tumor Phase 1/2 · NCT05275478 Terminated

Also used in these trials (approved or third-party drugs, not TNGX's own candidates): Abemaciclib, Olaparib, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TNGX holds $977.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $38M/quarter from operations, an estimated runway of 77.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TNGX files for a raise →

👥 Who Owns TNGX

Insiders 9.4% Other 5%+ holders 19% Institutions (354 holders) 71.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 25,286,624 14.92% 2026-10-30
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 16,270,187 9.60% 2026-06-30
Third Rock Ventures IV, L.P.
10% owner
Insider 13,386,574 7.90% 2025-10-23
RTW Investments, LP Institution (13G, 5%+) 13,300,620 7.85% 2026-03-31
Dapice Joshua J. 5%+ holder (13G) 11,257,203 6.64% 2026-03-31
Davis Aaron I. 5%+ holder (13D) 10,740,385 6.34% 2024-12-30
TCG Crossover GP II, LLC 5%+ holder (13G) 10,147,867 5.99% 2026-06-30
THE GOLDMAN SACHS GROUP, INC. Institution (13G, 5%+) 9,742,403 5.75% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 8,477,165 5.00% 2025-12-31
Barbara Weber
Director, Executive Chair, Director · +222,132 options
Insider 1,629,254 0.96% 2026-02-02
Malte Peters
President & CEO, Director · +1.84M options
Insider 367,500 0.22% 2026-01-08
Daniella Beckman
Chief Financial Officer · +265,980 options
Insider 184,297 0.11% 2026-02-02

Share count 169,455,160 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TNGX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TNGX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.